Analytical review of Prochlorperazine side effects and acute poisonings
DOI:
https://doi.org/10.24959/ubphj.19.214Keywords:
prochlorperazine, poisoning, side effects, chemical-toxicological analysisAbstract
Topicality. The article presents the analytical review data of the toxicological effects of prochlorperazine usage. Prochlorperazine is a sufficiently used drug with neuroleptic and antiemetic activity. It’s produced as a generic drug in many countries in the world in the form of tablets, suppositories and injection.
Aim. To conduct an analytical review of prochlorperazine side effects and acute poisonings of controlled and uncontrolled usage.
Results and discussion. According to information sources, in the period from 2010 till 2016 year were registered 258 cases of prochlorperazine acute poisoning in the world. The main causes of acute prochlorperazine poisoning noted with side effects of the treatment of it in therapeutic doses. Prochlorperazine is incompatible with drugs that suppress the central nervous system and increases the risk of neonatal complications if pregnant women use. Approximately 10 % of prochlorperazine numbers of acute poisonings are lethal cases of overdose. They are often due to suicide drug overdose. The drugs that were used simultaneously with prochlorperazine for suicide were defined: clonazepam, lorazepam, aprazolam, ibuprofen, naproxen, diazepam, seroquel, depacote, etc.
Conclusions. It is shown that if the methods of chemical-toxicological analysis of prochlorperazine will be presented in corresponding institutions of forensic medical expertise the number of registered cases of poisoning significantly increase, particularly in Ukraine.
References
1. European Monitoring Centre for Drugs and Drug Addiction. (2017). European Drug Report 2017. Available at: http://www.emcdda.europa.eu/system /files/publications/4541/TDAT17001ENN.pdf
2. Traxtenberg, Y. (2014). Nauka i praktyka,1, 22–37.
3. The United Nations Office on Drugs and Crime (UNODC). (2017). World Drug Report. Available at: https://www.unodc.org/wdr2017/field/Booklet_2_HEALTH.pdf
4. Dumanskyj, Yu., Kabanova, N. V., Verhuleczkyj, Y. E. (2012). Medycyna neotlozhnih sostoyanyj, 5, 121–132.
5. James, L. P., James, L., Abel, K., Wilkinson, J., Simpson, P. M., & Nichols, M. H. (2000). Phenothiazine, Butyrophenone, and Other Psychotropic Medication Poisonings in Children and Adolescents. Journal of Toxicology: Clinical Toxicology, 38(6), 615–623. https://doi.org/10.1081/clt-100102010 .
6. Vasylchenko, S., Pleten, V. A., Matvyjchuk, M. S. (2011). Medycyna neotlozhnih sostoyanyj,1–2, 152–153.
7. Olson, K. (2004). Poisoning & Drug Overdose. New York: Lange Medical Books/McGraw-Hill, 718 p.
8. Shcho vidomo pro efektyvnist ta bezpeku likarskykh zasobiv v Ukraini? (2018). Available at: https://www.apteka.ua/article/472756
9. Mashkovskij, M. D. (2008). Lekarstvennye sredstva: Posobie dlja vrachej. Moscow: Novaja volna, 1206.
10. Chekman, I., Gorchakova, N. O., Kazak L. I. (2011). Farmakologiya. Vinnycya: Nova knyga, 784.
11. Chekman, I., Belenychev, F., Gorchakova, N. (2018). Ostrye otravlenija lekarstvennymi preparatami : diagnostika, mery neotlozhnoj terapii. Kyiv, 100.
12. Ohlow, M., Moosmann, B. (2011). Phenothiazine: the seven lives of pharmacology's first lead structure. Drug Discovery Today, 16, 119–131. https://doi.org/10.1016/j.drudis.2011.01.001
13. Jaszczyszyn, A., Gąsiorowski, K., Świątek, P., Malinka, W., Cieślik-Boczula, K., Petrus, J., & Czarnik-Matusewicz, B. (2012). Chemical structure of phenothiazines and their biological activity. Pharmacological Reports, 64(1), 16–23. https://doi.org/10.1016/s1734-1140(12)70726-0
14. Chernykh, V. P. (2016). Farmatsevtychna entsyklopediia. Kyiv: «MORION», 1952.
15. Lindley, C., Goodin, S., McCune, J., Kane, M., Amamoo, M. A., Shord, S., Pham, T., Yowell, S., Laliberte, K., Schell, M., Bernard, S., Socinski, M. A. (2005). Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol., 28, 270–276.
16. Orr, S., Friedman, B. W., Christie, S. Minen, M. T., Bamford, C., Kelley, N. E., Tepper, D. (2016). Management of adults with acute migraine in the emergency department: the American headache society evidence assessment of parenteral pharmacotherapies. Headache, 56, 911–940. https://doi.org/10.1111/head.12835
17. Chua, A. L., Silberstein, S. (2016). Inhaled drug therapy development for the treatment of migraine. Expert Opinion on Pharmacotherapy, 17, 1733–1743. https://doi.org/10.1080/14656566.2016.1203901
18. Patniyot, I. R., Gelfand, A. A. (2016). Acute Treatment therapies for pediatric migraine: a qualitative systematic review. Headache, 56, 49–70. https://doi.org/10.1111/head.12746
19.Vertyneks. Kusum Kheltkhker. (n.d.). Available at: https://compendium.com.ua/info/220097/vertineks-sup-sup-
20.Prokhlorperazyn. Mizhnarodni nazvy. (n.d.). Available at:https://www.drugs.com/international/prochlorperazine.html
21. Likarski formy ta dozuvannia prokhlorperazynu. (n.d.). Available at:https://www.drugs.com/dosage/prochlorperazine.html
22.Pobichni efekty prokhlorperazynu. (2018). Available at: https://www.rxlist.com/compazine-drug/patient-images-side-effects.htm
23.Pobichni efekty prokhlorperazynu. (n.d.). Available at:http://patientsville.com/medication/prochlorperazine_side_effects.htm#.W9oSXzFwnIU
24.Pobichni efekty prokhlorperazynu. (n.d.). Available at: https://www.ehealthme.com/drug/prochlorperazine/side-effects/
25.Pobichni efekty prokhlorperazynu. (n.d.). Available at: https://www.everydayhealth.com/drugs/prochlorperazine
26. Yomiya, K., Takei, D., Kurosawa, H, Kono, B. (2013). A study on the antiemetic effect and extrapyramidal symptoms of prochlorperazine versus perospirone for the control of nausea and vomiting due to opioid introduction. Gan To Kagaku Ryoho, 40, 1037–1041.
27. Frithsen, I., Simpson, W. M. (2010). Recognition and management of acute medication poisoning. Am Fam Physician., 81, 316–323.
28. Mindikoglu, A., Anantharaju, A., Hartman, G. G. , Li, S. D., Villanueva, J., Van Thiel, D. H. (2003). Prochlorperazine-induced cholestasis in a patient with alpha-1 antitrypsin deficiency. Hepatogastroenterology, 50, 1338–1340.
29. Pobichni efekty prokhlorperazynu. (n.d.). Available at: http://pennstatehershey.adam.com/content.aspx?productId=117&pid=1&gid=002615
30. Nakanuno, R., Ito, T., Matsunaga, A., Kawamoto, M. (2010). Antiemetic-induced extrapyramidal symptoms seen by our palliative care team. Masui, 59, 645–647.
31. Lacasse, H., Perreault, M. M., Williamson, D. R. (2006). Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. Ann Pharmacother, 40, 1966–1973.https://doi.org/10.1345/aph.1h241
32. Muñiz, A. (2000). Prochlorperazine-induced extrapyramidal effects mimicking meningitis in a child. Southern Medical Journal, 93, 629–630.https://doi.org/10.1097/00007611-200093060-00022
33. Lau Moon Lin, M., Robinson, P. D., Flank, J., Sung, L., Dupuis, L. L. (2016). The safety of prochlorperazine in children: a systematic review and meta-analysis. Drug safety, 39 (6), 509–516. https://doi.org/10.1007/s40264-016-0398-9 .
34. Briggs, G., Freeman, R., Yaffe, S. (2011). Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Wolters Kluwer, Lippincott Williams & Wilkins, 1728.
35. Iliaszenko, J., Sokołowska, M., Paruszewski, R. (2001). Gravimetric and spectrophotometric determination of some phenothiazine and imidazole derivatives in coated tablets and tablets. Acta Pol Pharm, 58, 411–413.
36. Bhagwat, G. B.(2013). UV Spectrophotometric analysis of Prochlorperazine Maleate and Pyridoxine Hydrochloride in tablet dosage form by simultaneous equation method. Int J ChemTech Res., 5, 2309–2316.
37. Luminita, B., Claudia, M. G., MihaelaIlie, D., Luiza, B. I. (2009). Qualitative and semi quantitative TLC analysis of certain phenothiazines in human plasma. Farmacia, 57, 542–548.
38. Dhabab, J. M, Al-Ameri, A. H., Taufeeq, A. H., Asso, J. (2013). Separation and determination of Trifluoperazine and Prochlorperazine in pharmaceutical preparations by HPLC. Arab Uni. for basic & app. sci., 13, 14–18. https://doi.org/10.1016/j.jaubas.2012.08.002
39. Patel, V. D., Patel, P.U. (2014). Development and validation of reverse phase high performance liquid chromatography method for simultaneous estimation of Betahistine Dihydrochloride and Prochlorperazine maleate in tablet dosage form. Int J Pharm. & drug anal.,2, 369–374.
40. Ruri, A., Tetsuya, A., Takeshi, K., Hideki, H., Hiroshi, N. (2007). An automated on-line method for simultaneous analysis of phenothiazines in human serum by high-performance liquid chromatography. Forensic Toxical., 25, 8–15. https://doi.org/10.1007/s11419-007-0020-z .
41. Suresh, R., Sree, V. J., Manavalan, R., Vallippan, K. (2010). Aspect of validation in HPLC method development for pharmaceutical analysis- comparison of validation requirements by FDA, USP And ICH. Inter. J. Pharm. Science,1, 123–132.
42. Zavialova, O., Zielińska, J. (2001). Conductometric determination of phenothiazine derivatives. Acta Polon Pharm -Drug Res., 58, 157–161.
43. Yang ,Y., Peng, Y., Zhao, F, Zeng, B. (2003). Voltammetric determination of prochlorperazine and ethopropazine using a gold electrode modified with Decanethiol SAM. Sensors, 3 524–533. https://doi.org/10.3390/s31100524
44. Francisco, J., Lara, A., Garc, C., Laura, G., Juan, M., Bosque, S., Ferm, N. (2006). Formulations and Human urine using capillary electrophoresis with chemiluminescence’s detection. Electrophoresis, 27, 2348–2359. https://doi.org/10.1016/j.jaubas.2012.08.002
45. Yan, M., Zhu, Y. G., Li, H. D., Chen, B. M., Ma, N., Lei, Y. Q., Liu, Y. P. (2009). Quantification of prochlorperazine maleate in human plasma by liquid chromatography-mass spectrometry: Application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci.,877, 3243–3247. https://doi.org/10.1016/j.jchromb.2009.07.038
46. Tashiro, M., Naito, T., Kagawa, Y., Kawakami, J. (2012). Simultaneous determination of Prochlorperazine and its metabolites in human plasma using isocratic liquid chromatography tandem mass spectrometry. Biomed Chromatogr., 26, 754–760. https://doi.org/10.1002/bmc.1725
Downloads
Published
Issue
Section
License
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
